BiondVax Pharma (BVXV) Reports Q1 Loss of NIS0.03/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/2/2026
- S&P 500, Dow rise as AI boost counters US-Iran tensions
- Oil rises, as US-Iran strikes risk limiting already impaired supplies
- Dell again lifts annual forecasts as AI demand powers record results
- Could Apple’s foldable iPhone be a $14B opportunity? Morgan Stanley weighs in
- Uber stock gains 2% as tech giant cuts 3,300 jobs in major restructuring
BiondVax Announces First Quarter 2015 Financial Results
June 1, 2015 6:10 AM EDTNES ZIONA, Israel, June 1, 2015 /PRNewswire/ --Â BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV, TASE: BNDX), a clinical stage biopharmaceutical company focused on developing and commercializing immunomodulation therapies for infectious diseases, today announced its financial results for the first quarter of 2015 and provided a business update.
First Quarter 2015 Financial Summary
Results are in New Israel Shekels (NIS) and a convenience translation to US$ is provided, using the exchange rate of 3.98 as at March 31, 2015
Total operating expenses were NIS 1.82m ($457,000) compared with... More